(ANAB) AnaptysBio - Ratings and Ratios
Antibody, Autoimmune, Inflammation, Dermatology, Phase
ANAB EPS (Earnings per Share)
ANAB Revenue
Description: ANAB AnaptysBio October 22, 2025
AnaptysBio, Inc. (NASDAQ: ANAB) is a clinical-stage biotech based in San Diego that develops antibody-based immunology therapeutics. Its platform targets checkpoint and cytokine pathways implicated in autoimmune and inflammatory diseases.
The current pipeline includes: Rosnilimab (PD-1 agonist/depleting IgG1), ANB032 (non-depleting BTLA antibody), ANB033 (anti-CD122 antagonist affecting IL-15/IL-2 signaling), ANB101 (BDCA2 modulator for plasmacytoid dendritic cells), and Imsidolimab (IL-36 receptor blocker in Phase 3 for generalized pustular psoriasis). The company also leverages a collaboration and license agreement with GlaxoSmithKline (GSK) that provides milestone payments and shared development costs.
Recent financial data (Q2 2024) show a cash balance of approximately $115 million, a net cash burn of $45 million YoY, and R&D expenses representing ~55 % of total operating costs-typical for a firm with multiple Phase 1/2 programs. The market-cap sits near $300 million, implying a price-to-cash-burn multiple of ~6.5×, which is modest relative to peers with comparable cash run-off.
Key sector drivers include the expanding market for targeted immunotherapies (projected CAGR ≈ 12 % through 2030) and a favorable regulatory environment for biologics, especially in dermatology and autoimmune indications. However, execution risk remains high: Phase 3 success rates for novel checkpoint antibodies are historically below 30 %, and the company’s reliance on a single large partner (GSK) adds concentration risk.
For a deeper quantitative view of ANAB’s risk-adjusted upside, you may find ValueRay’s analyst toolkit useful for independent validation.
ANAB Stock Overview
| Market Cap in USD | 1,023m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2017-01-26 |
ANAB Stock Ratings
| Growth Rating | 37.3% |
| Fundamental | 42.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 56.1% |
| Analyst Rating | 4.42 of 5 |
ANAB Dividends
Currently no dividends paidANAB Growth Ratios
| Growth Correlation 3m | 92.5% |
| Growth Correlation 12m | 65% |
| Growth Correlation 5y | -26.7% |
| CAGR 5y | 8.67% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.13 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.26 |
| Sharpe Ratio 12m | -0.96 |
| Alpha | 97.54 |
| Beta | -0.169 |
| Volatility | 73.66% |
| Current Volume | 377.9k |
| Average Volume 20d | 309.5k |
| Stop Loss | 37.5 (-5.4%) |
| Signal | -0.23 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-132.6m TTM) > 0 and > 6% of Revenue (6% = 7.39m TTM) |
| FCFTA -0.38 (>2.0%) and ΔFCFTA -7.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 208.2% (prev 1073 %; Δ -864.7pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.38 (>3.0%) and CFO -127.7m > Net Income -132.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (28.8m) change vs 12m ago 5.32% (target <= -2.0% for YES) |
| Gross Margin 99.03% (prev 92.14%; Δ 6.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 32.30% (prev 7.13%; Δ 25.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.98 (EBITDA TTM -66.5m / Interest Expense TTM 70.5m) >= 6 (WARN >= 3) |
Altman Z'' -6.65
| (A) 0.76 = (Total Current Assets 291.9m - Total Current Liabilities 35.5m) / Total Assets 335.2m |
| (B) -2.50 = Retained Earnings (Balance) -837.3m / Total Assets 335.2m |
| warn (B) unusual magnitude: -2.50 — check mapping/units |
| (C) -0.18 = EBIT TTM -69.0m / Avg Total Assets 381.3m |
| (D) -2.20 = Book Value of Equity -837.3m / Total Liabilities 380.0m |
| Total Rating: -6.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 42.57
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -11.60% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity -7.74 = -2.50 |
| 5. Debt/Ebitda -4.54 = -2.50 |
| 7. RoE -367.0% = -2.50 |
| 8. Rev. Trend 88.11% = 6.61 |
| 9. EPS Trend 49.25% = 2.46 |
What is the price of ANAB shares?
Over the past week, the price has changed by +10.02%, over one month by +24.80%, over three months by +98.25% and over the past year by +77.01%.
Is AnaptysBio a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ANAB is around 44.38 USD . This means that ANAB is currently undervalued and has a potential upside of +11.93% (Margin of Safety).
Is ANAB a buy, sell or hold?
- Strong Buy: 7
- Buy: 3
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ANAB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 65.7 | 65.8% |
| Analysts Target Price | 65.7 | 65.8% |
| ValueRay Target Price | 48.1 | 21.4% |
ANAB Fundamental Data Overview November 04, 2025
P/S = 8.308
P/B = 114.7281
Beta = -0.169
Revenue TTM = 123.2m USD
EBIT TTM = -69.0m USD
EBITDA TTM = -66.5m USD
Long Term Debt = 15.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.00m USD (from shortTermDebt, last quarter)
Debt = 346.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 302.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.10b USD (1.02b + Debt 346.5m - CCE 265.7m)
Interest Coverage Ratio = -0.98 (Ebit TTM -69.0m / Interest Expense TTM 70.5m)
FCF Yield = -11.60% (FCF TTM -128.1m / Enterprise Value 1.10b)
FCF Margin = -104.0% (FCF TTM -128.1m / Revenue TTM 123.2m)
Net Margin = -107.7% (Net Income TTM -132.6m / Revenue TTM 123.2m)
Gross Margin = 99.03% ((Revenue TTM 123.2m - Cost of Revenue TTM 1.20m) / Revenue TTM)
Gross Margin QoQ = 97.30% (prev 100.0%)
Tobins Q-Ratio = 3.29 (Enterprise Value 1.10b / Total Assets 335.2m)
Interest Expense / Debt = 5.66% (Interest Expense 19.6m / Debt 346.5m)
Taxrate = -0.10% (negative due to tax credits) (39.0k / -38.6m)
NOPAT = -69.0m (EBIT -69.0m * (1 - -0.10%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 8.22 (Total Current Assets 291.9m / Total Current Liabilities 35.5m)
Debt / Equity = -7.74 (negative equity) (Debt 346.5m / totalStockholderEquity, last quarter -44.7m)
Debt / EBITDA = -4.54 (negative EBITDA) (Net Debt 302.2m / EBITDA -66.5m)
Debt / FCF = -2.36 (negative FCF - burning cash) (Net Debt 302.2m / FCF TTM -128.1m)
Total Stockholder Equity = 36.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.55% (Net Income -132.6m / Total Assets 335.2m)
RoE = -367.0% (Net Income TTM -132.6m / Total Stockholder Equity 36.1m)
RoCE = -134.6% (out of range, set to none) (EBIT -69.0m / Capital Employed (Equity 36.1m + L.T.Debt 15.1m))
RoIC = -191.0% (out of range, set to none) (NOPAT -69.0m / Invested Capital 36.1m)
WACC = 5.46% (E(1.02b)/V(1.37b) * Re(5.39%) + D(346.5m)/V(1.37b) * Rd(5.66%) * (1-Tc(-0.00)))
Discount Rate = 5.39% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 4.10%
Fair Price DCF = unknown (Cash Flow -128.1m)
EPS Correlation: 49.25 | EPS CAGR: 28.98% | SUE: 2.92 | # QB: 1
Revenue Correlation: 88.11 | Revenue CAGR: 181.5% | SUE: 0.70 | # QB: 0
Additional Sources for ANAB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle